How Do Pretransplantation Peripheral Blood Counts Inform Us about Post-Transplantation Outcomes in Acute Myeloid Leukemia?

Abstract

received consolidation and 86% had response improvement within 1 cycle. At 12 months, the complete response rate was 58% and at 24 months, organ response rates were 70%. The major barrier to widespread implementation of stem cell transplantation is the high treatment-related mortality. In the current article, Sanchorawala et al. report therapy-related mortality of 8.5%. The group from Oregon had therapy-related mortality of 9.6% [7], and the group at Memorial reported 10% treatment-related mortality [8]. These therapy-related mortality rates are increasingly difficult to justify as new active agents for the treatment of immunoglobulin light chain amyloidosis become available. It will be important to properly select patients at high risk of therapy-related death for exclusion to achieve the optimal outcomes when combining new antiplasma cell agents with myeloablative therapy and stem cell rescue.